Diamond Pharma Services
Diamond are a leading European technical and regulatory affairs consultancy with extensive experience in the development of advanced therapies, including supporting the development & marketing authorisation for both the first gene therapy (Glybera) and CAR-T (Yescarta) to be approved in Europe. Overall we have supported more than 45 gene, and gene modified cell therapy programmes. Our specialised team has broad and varied industry experience offering both breadth and depth of expertise, from which our clients benefit. Diamond offers a comprehensive service including regulatory affairs, product development (nonclinical, CMC and clinical), pharmacovigilance and quality & compliance.